The FDA has approved Lilly’s Verzenio, making it the third market entrant in a new class of drugs for breast cancer. Verzenio (abemaciclib) is now licensed to treat adult patients with hormone ...

Verzenio (abemaciclib) is not chemotherapy. It’s also not immunotherapy. Rather, it’s a targeted type of treatment for specific forms of breast cancer. Verzenio is known as a targeted ...

As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...